Piperidines

Apexbio Technology LLC SAR7334 1333210-07-3 2mg

SAR7334 (CAS 1333210-07-3) is a small molecule inhibitor that selectively targets the transient receptor potential cation channel subfamily C member 6 (TRPC6) By inhibiting TRPC6-mediated calcium influx SAR7334 is utilized to investigate TRPC6-related signal transduction pathways in cellular and preclinical studies This compound serves as a valuable tool for elucidating the role of TRPC6 in pathophysiological processes including those related to kidney function and vascular regulation Its application aids in advancing the understanding of TRPC6-associated diseases and potential therapeutic interventions

Medchemexpress LLC 3-[1-[(3S)-1-prop-2-enoylpyrrolidin-3-yl]oxyisoquinolin-3-yl]-1,4-dihydro-1,2,4-triazol-5-one | 1627603-21-7 | 99.9% | C18H17N5O3 | 10MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

TAK-020 is a covalent Bruton's tyrosine kinase (BTK) inhibitor developed by Takeda and advanced as a clinical candidate for hematologic malignancies and autoimmune diseases. It irreversibly binds Cys481 in BTK's ATP-binding site and is provided by research suppliers as a characterized small-molecule reagent (CAS 1627603-21-7).

• Covalent inhibitor that targets Cys481 in BTK.
• Selective BTK inhibition supported by preclinical and clinical data.
• Well-characterized small molecule with published analytical reports.
• Available from vendors in mg-scale quantities for research use.
• Typically supplied as high-purity material for in vitro and in vivo studies.